Cadila Healthcare launches anti-depressant tablets

Ahmedabad: Cadila Healthcare Ltd (Zydus Cadila) on Monday announced the first day launch of Venlafaxine Hydrochloride tablets upon receiving the final approval from the US Food and Drug Administration (USFDA). The company is marketing the product in the strengths of 25, 37.5, 50,75 and 100 mg in the US market.

The sales of Venlafaxine hydrochloride, an anti-depressant, was estimated at $194 million in 2007, it said here in a statement.

This marks the 39th Abbreviated New Drug Application (ANDA) approval for the Group since the commencement of filing process in FY 2003-04. So far, the group has filed 78 ANDAs and 59 Drug Master Files.